Compare Carvana Co (CVNA) vs Johnson & Johnson (JNJ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Carvana Co vs Johnson & Johnson — how do they compare? Carvana Co trades at $63.73 (market cap $69.55B), while Johnson & Johnson trades at $261.44 (market cap $618.09B). The key difference: Johnson & Johnson is far larger — about 8.9× Carvana Co's market cap, and Johnson & Johnson pays a 2.09% dividend while Carvana Co pays none. Which is the better fit depends on your goals — on Pluang, investors hold Carvana Co for 28 Days and Johnson & Johnson for 129 Days on average.
| CVNA | JNJ | |
|---|---|---|
Market Cap | $69.55B | $618.09B |
Volume | 7,671,750 | 6,050,983 |
Sector | Consumer Cyclical | Health |
52-Week High | $95.69 | $278.43 |
52-Week Low | $56.27 | $186.00 |
Typical Hold Time | 28 Days | 129 Days |
Enterprise Value | $72.04B | $646.37B |
Dividend Yield | — | 2.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Carvana (CVNA) trades at $63.21, up 0.72% with strong fundamental momentum including 10 consecutive quarters of record profitability. Revenue surged 52% in Q2 FY26 to $20.32B annually, while net income reached $1.41B with a 6.26% margin. Technical indicators show bearish momentum with key support at $61-62, though RSI levels remain neutral. The company continues expanding capacity to meet robust demand, with same-day delivery recently launched in Minneapolis.
CVNA presents growth potential with analyst consensus target of $84.07 (33% upside), but faces risks from high debt levels ($5.26B long-term) and volatile cash flow patterns. The stock's elevated P/E of 33.44 and EV/EBITDA of 507.31 suggest premium valuation, requiring sustained execution to justify. Competitive pressures in online auto retail and interest rate sensitivity remain key watchpoints for investors.
Johnson & Johnson (JNJ) trades at $256.48, down 0.76% today, with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with 28.45% net profit margin and consistent revenue growth to $94.19B in 2025. Analyst consensus remains positive with a $286.53 price target, though technical indicators show resistance at $258 and support at $253. Recent news highlights pipeline strength including Icotyde's $4.5B peak sales potential (Bank of America, 2026-09-29).
JNJ presents a compelling long-term investment with diversified healthcare exposure and dividend stability, though near-term technical weakness and patent cliff concerns warrant caution. The 52.5% buy rating from analysts reflects confidence in innovation pipeline, while debt-to-asset ratio increase to 24.06% merits monitoring. Upside potential exists if Q3 earnings beat expectations on October 13.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Carvana Co
Carvana Co is an e-commerce platform for buying and selling used cars. The company derives revenue from used vehicle sales, wholesale vehicle sales and other sales and revenues. The other sales and revenues include sales of loans originated and sold in securitization transactions or to financing partners, commissions received on VSCs and sales of GAP waiver coverage.
Read more on CVNA →About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →
